Irisin prevents dexamethasone-induced atrophy in C2C12 myotubes

被引:0
作者
Jae Seung Chang
In Deok Kong
机构
[1] Yonsei University Wonju College of Medicine,Department of Physiology
[2] Yonsei Institute of Sports Science & Exercise Medicine,Mitohormesis Research Center
[3] Yonsei University Wonju College of Medicine,undefined
来源
Pflügers Archiv - European Journal of Physiology | 2020年 / 472卷
关键词
Muscle atrophy; Irisin; Glucocorticoid; FoxO3α; Atrogin-1/MAFbx; MuRF-1;
D O I
暂无
中图分类号
学科分类号
摘要
Irisin is a myokine secreted mainly from skeletal muscle that is known for having beneficial metabolic effects via enhancement of energy expenditure and insulin sensitivity. Studies show that irisin also acts as an autocrine/paracrine to promote myogenesis and muscle growth. However, the protective role of irisin against muscular wasting remains unclear. We confirmed that irisin secretion was upregulated by electrical pulse stimulation an in vitro exercise mimetic model. Next, we tested if irisin exerted an anti-atrophic effect on cultured C2C12 myotubes treated with dexamethasone (DEX), a representative inducer of muscular atrophy. Treatment of cultured myotubes with DEX reduced myotube size and increased proteasome activity, which were attenuated by irisin. Also, irisin effectively prevented dephosphorylation of forkhead box O (FoxO) 3α and upregulation of muscle-specific ubiquitin ligases in DEX-treated myotubes. The protective effect of irisin on DEX-mediated myotube atrophy was partially regulated by insulin-like growth factor-1-dependent signaling. These results suggested that irisin may prevent glucocorticoid-induced muscle atrophy by inhibiting FoxO-mediated ubiquitin-proteasome overactivity.
引用
收藏
页码:495 / 502
页数:7
相关论文
共 226 条
[11]  
Choi JH(2011)Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia J Am Med Dir Assoc 12 344-1738
[12]  
Long JZ(2003)Molecular mechanisms modulating muscle mass Trends Mol Med 9 1725-1544
[13]  
Kajimura S(2012)FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise Metabolism 61 1538-896
[14]  
Zingaretti MC(2014)Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans Int J Obes 38 889-740
[15]  
Vind BF(2002)Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability J Am Geriatr Soc 50 734-7
[16]  
Tu H(2015)Detection and quantitation of circulating human irisin by tandem mass spectrometry Cell Metab 22 1-1107
[17]  
Cinti S(2014)Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes Peptides 56 1091-885
[18]  
Hojlund K(2014)Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies J Physiol 592 869-4020
[19]  
Gygi SP(2016)The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death Cell Res 26 7816806-364
[20]  
Spiegelman BM(2018)Irisin a novel metabolic biomarker: present knowledge and future directions Int J Endocrinol 2018 4007-331